Loading company…
Tachyon Therapeutics develops cancer treatments targeting new areas of cancer biology.
Tachyon Therapeutics develops therapies targeting new drug targets in cancer biology and offers single-cell genomic analysis technology. Its approach aims to reduce cancer stem cells associated with relapse and metastasis. Based in San Francisco, it was founded in 2020. In March 2023, it raised USD 11.6 million from Khosla Ventures, Red Tree Venture Capital, and Veblen Ventures to advance drug candidates and a Phase 1 trial in advanced solid tumours.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in